Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Study Details
Study Description
Brief Summary
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Detailed Description
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Phase 1 is a standard cohort dose escalation 3+3 design with a modified Fibonacci dose escalation used to determine the maximum tolerated dose to select a recommended Phase 2 dose (RP2D) for Phase 2a and Phase 2b. The initial dose of NEO212 will be 170mg and the dose will increase in successive cohorts (220, 400, 610, 810, and 1,000mg) until a MTD is reached and a RP2D is selected. There will be up to 42 patients enrolled in Phase 1. In the event two DLTs are experienced in any cohort, a dose de-escalation cohort will be followed (with half of the dose increase from the previous cohort) to determine the MTD/RP2D.
Phase 2a is a safety run-in study with a standard 3+3 design used to confirm the safety of the MTD/RP2D of NEO212 when given in combination with select SOC regimens for patients with uncontrolled brain metastasis. There will be up to 12 patients enrolled into each combination regimen to confirm safety. One dose below the NEO212 MTD/RP2D Cohort Dose will be administered as a starting dose to establish safety (3+3), before moving to Phase 2b with the MTD/RP2D (3+3). In the event that two DLTs are experienced for patient receiving the MTD/RP2D in combination with SOC, the dose de-escalation cohort will be expanded to determine the MTD for a newly established Phase 2b Treatment Group.
Phase 2b is a dose expansion study to assess efficacy of NEO212, at the MTD/RP2D in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype as a single Treatment Group. A second Treatment Group to study the MTD/RP2D of NEO212 in combination with select SOC regimens in patients with solid tumors and uncontrolled brain metastasis established in Phase 2a will be evaluated. Phase 2b will be initiated for patients with Astrocytoma IDH-mutant or Glioblastoma IDH-wildtype alongside Phase 2a. There will be up to 28 patients enrolled to have 27 evaluable patients enrolled in each Phase 2b Treatment Group.
For all phases of the study, NEO212 will be self-administered daily for days 1-5 of a 28-day treatment cycle.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Phase 2a Safety Run-In - NEO212 and Ipilimumab - Unresectable or metastatic melanoma with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Ipilimumab
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Other Names:
|
| Experimental: Phase 2a Safety Run-In - NEO212 and Pembrolizumab The following primary cancers with uncontrolled metrastases to the brain: Unresectable or metastatic melanoma. NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations. Metastatic NSCLC whose tumors express PD-L1. EGFR or ALK genomic tumor aberrations must have disease progression. SCLC. Unresectable, recurrent HNSCC whose tumors express PD-L1. HNSCC on or after platinum-containing chemotherapy. Urothelial carcinoma whose tumors express PD-L1. Urothelial carcinoma. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Microsatellite Instability-high or Mismatch Repair Deficient Colorectal Cancer (CRC). Gastric or gastroesophageal junction adenocarcinoma. Esophageal or gastroesophageal juncUon (GEJ). Cervical cancer. Merkel cell carcinoma. NEO212 - Same as Arm 1. Pembrolizumab - 200 mg administered every 3 weeks per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Pembrolizumab
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Other Names:
|
| Experimental: Phase 2a Safety Run-In - NEO212 and Nivolumab The following primary cancers with uncontrolled metrastases to the brain: Unresectable or metastatic melanoma. Metastatic non-small cell lung cancer. Advanced renal cell carcinoma. Squamous cell carcinoma of the head and neck. Urothelial carcinoma. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Unresectable esophageal squamous cell carcinoma (ESCC). NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Nivolumab - 240 mg administered every 2 weeks per package insert |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Nivolumab
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Other Names:
|
| Experimental: Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib) - Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Regorafenib
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Other Names:
|
| Experimental: Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol) - Colorectal cancer (CRC) with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert. Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Carboplatin
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Other Names:
Drug: Paclitaxel
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Other Names:
|
| Experimental: Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin) - Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks. Bevacizumab - 10 mg/kg IV every 2 weeks. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: FOLFIRI Protocol
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:
FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Other Names:
Drug: Bevacizumab
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Other Names:
|
| Experimental: Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
|
| Experimental: Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b. |
Drug: NEO212 Oral Capsule
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Other Names:
Drug: Ipilimumab
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Other Names:
Drug: Pembrolizumab
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Other Names:
Drug: Nivolumab
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Other Names:
Drug: Regorafenib
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Other Names:
Drug: Carboplatin
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Other Names:
Drug: Paclitaxel
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Other Names:
Drug: FOLFIRI Protocol
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:
FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Other Names:
Drug: Bevacizumab
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain [6 months]
As determined by incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0
- Phase 1: Identify the maximum tolerated dose (MTD) of NEO212 [6 months]
Maximum Tolerated Dose of NEO212 as determined by the dose escalation rules.
- Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212 [6 months]
Determine the recommended Phase 2 dose (RP2D) of NEO212
- Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain [6 months]
Determined by incidence and severity of adverse events determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0).
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype. [6 months]
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.
- Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain. [6 months]
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors (see Appendix 2) with uncontrolled metastases to the brain.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Phase 1: (dose escalation)
-
Patient must be ≥ 18yrs of age.
-
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
-
Patient must:
• have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
• have select solid tumors (see Appendix 2) with uncontrolled brain metastasis (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
-
Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:
• 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
• 2 weeks from administration of immunotherapies;
• 28 days from administration of cytotoxic agents; and
• 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).
-
Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
-
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
-
Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
-
Patient with select solid tumors (see Appendix 2) must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Patient must have an expected survival or at least three months.
-
Patient must have a baseline MRI with gadolinium within 14 days of administration of NEO212.
-
Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
-
Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
-
Patient must be willing to provide blood samples for pharmacokinetic study.
-
If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
-
Patient must have adequate organ and marrow function as follows:
• Absolute neutrophil count ≥ 1,500/microliter
• Platelets ≥ 100,000/microliter
• Total bilirubin within normal institutional limits
• AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
• Serum creatinine ≤ x ULN and creatinine clearance (CrCl) of >50 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).
- Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
• A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
o Has not undergone a hysterectomy or bilateral oophorectomy; or
o Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
-
A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
-
A serum pregnancy test will be repeated immediately if pregnancy is suspected.
Phase 2a: (safety run-in)
-
Patient must be ≥ 18yrs of age.
-
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
-
Patient must have select solid tumors (see Appendix 2) with uncontrolled brain metastasis (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patient been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
-
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens listed on Appendix 1.
-
Any toxicity attributed to prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
-
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
-
Patient with select solid tumors (see Appendix 2) must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Patient must have an expected life-expectancy of at least three months.
-
Patient must have a baseline MRI with gadolinium within 14 days of administration of NEO212.
-
Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
-
Patient must have measurable/evaluable CNS disease per RANO criteria.
-
Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
-
Patient must be willing to provide blood samples for pharmacokinetic study.
-
If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
-
Patient must have adequate organ and marrow function as follows:
• Absolute neutrophil count ≥ 1,500/microliter
• Platelets ≥ 100,000/microliter
• Total bilirubin within normal institutional limits
• AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
- Serum creatinine ≤ x ULN and creatinine clearance (CrCL) of >50 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).
- Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
• A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
o Has not undergone a hysterectomy or bilateral oophorectomy; or
-
Has been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
-
A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
-
A serum pregnancy test will be repeated immediately if pregnancy is suspected.
Phase 2b: (efficacy)
-
Patient must be ≥ 18yrs of age.
-
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
-
Patient must:
-
have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
-
have select solid tumors (see Appendix 2) with uncontrolled brain metastasis (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
-
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens listed on Appendix 1.
-
Any toxicity attributed to prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
-
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
-
Patient with select solid tumors (see Appendix 2) must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Patient must have an expected survival or at least three months. 9. Patient must have a baseline MRI with gadolinium within 14 days of administration of 10. Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212. 11. Patient must have measurable/evaluable CNS disease per RANO criteria. 12. Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria. 13. Patient must be willing to provide blood samples for pharmacokinetic study. 14. If patient suffers from seizures (s)he must be controlled on a stable dose of antiepileptics for 14-days prior to the date of informed consent.
-
Patient must have adequate organ and marrow function as follows:
• Absolute neutrophil count ≥ 1,500/microliter
• Platelets ≥ 100,000/microliter
• Total bilirubin within normal institutional limits
-
AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal 16. Serum creatinine ≤ x ULN and creatinine clearance (CrCl) of >50 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
-
A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
-
Has not undergone a hysterectomy or bilateral oophorectomy; or
-
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
-
A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
-
A serum pregnancy test will be repeated immediately if pregnancy is suspected.
Exclusion Criteria:
-
Patient in Phase 1 concurrently receiving any other antitumor therapy.
-
Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
-
Patient has had more than one recurrence or progression of his/her CNS tumor(s).
-
Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
-
Patient with history of known leptomeningeal involvement.
-
Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
-
Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of
470 msec, , a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval.
-
Patient had surgery within 7 days prior to the date of informed consent.
-
Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
-
Patient had prior treatment with perillyl alcohol.
-
Patient has a history of allergic reactions attributed to perillyl alcohol.
-
Patients with an autoimmune disease that required systemic therapy or a medical condition that requires immunosuppression.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Neonc Technologies, Inc.
Investigators
- Study Chair: Tom Chen, MD, PhD, NeOnc Technologies
- Study Director: Vincent Simmons, PhD, NeOnc Technologies
- Study Director: Patrick Walters, NeOnc Technologies
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NEO212-01